Hoverink Biotechnologies, Inc., today announced that they have completed an application with the USPTO for MAXKAFLEN®. Hoverink Biotechnologies, Inc plans to develop and commercialize MAXKAFLEN® a cattle and swine antibiotic.
November 12, 2018 14:30 ET
|
Hoverink Biotechnologies, Inc
Overview LOS ANGELES, CA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- On September 26, 2018 We filed trademark applications covering: MAXKAFLEN® Word Mark MAXKAFLEN Goods and Services IC 005....